

Breast Cancer

	Endocrine Therapy	ER/PR-POSITIVE HER2 NEGATIVE	HER2 POSITIVE	"TRIPLE NEGATIVE" EP/PR -NEGATIVE HER2-NEGATIVE	
Pre-Op Therapy	No Trial Currently Available	IRB#6256 -ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular			
Surgical Therapy	IRB#9340 - Phase II breast conservation surgery and radiation therapy study				
Adjuvant Therapy	No Trial Currently Available		IRB#15366 Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (Applies to Adjuvant, 1 st line and beyond HER2 + MBC therapy)	No Trial Currently Available	
1st line MBC Therapy	IRB # 16390 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer	IRB#11351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced		IRB # 17016 COMPLEEMENT-1: An open -label Phase 3 to evaluate safety and efficacy of ribociclib in compination with	IRB#11351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer
2nd line MBC Therapy		IRB#16379 C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor		No Trial Currently Available	
3rd line MBC Therapy	No Trial Currently Available			No Trial Currently Available	
"Heavily Pre-treated" Therapy	No Trial Currently Available		No Trial Currently Available	No Trial Currently Available	

Key

- Open for Enrollment
- In Development
- Enrollment on Hold